Meeting Report
The Menarini Asia Pacific Advancing Patient care with EdoXaban (APEX) 2023 Expert Meeting convened in Kuala Lumpur, Malaysia, and provided a forum for experts to explore the occurrence of gastrointestinal bleeding linked to non-vitamin K antagonist oral anticoagulants in Asian clinical practice for stroke prevention in atrial fibrillation. This report amalgamates insights from two segments of the meeting.
Case Series
The authors share early clinical experiences with once-daily edoxaban and discuss its evidence-based use in patients with non-valvular atrial fibrillation in Southeast Asia through several cases of patients at high risk
Letter-to-the-Editor
Letter to the Editor commenting on Orsucci D, Caldarazzo Ienco E, Nocita G, Napolitano A, Vista M. Neurological features of COVID-19 and their treatment: a review. Drugs Context. 2020;9:2020-5-1.
Review
This review aims to summarize early findings on
the neurological features of COVID-19 and their treatment
approaches.
Original Research
The aim of this study was to assess whether the recommendations and guidelines for thromboprophylaxis in patients with atrial fibrillation (AF) have been adopted in general practice (GP) in the UK. The authors concluded that one in four patients with non-valvular AF, at risk of a stroke, is not being adequately treated with an oral anticoagulant in primary care and suggest that a review of GP practice databases should be considered to identify patients with non-valvular AF, at risk of a disabling or fatal event, and measures taken to initiate anticoagulant therapy.
